Watch PBSV. Know when insiders buy.
One email the day a filing lands. Free.
PBSV
Pharma-Bio Serv, Inc.
0.40
−0.05 −11.11%
USD · close Nov 6
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.2MP/E 40.0DIV YIELD —FCF YIELD -4.60%REV TTM $9.5M +3.3%NET INCOME $252KNET CASH —52W 0.35 – 0.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jul 31 | $2.3M | +19.0% | 29.6% | −$72K | −$14K | — | -0.00 | $61K | $1K | $60K | Sep 14 |
| Q2 2026 · Apr 30 | $2.7M | +11.8% | 33.4% | $145K | $233K | +144.3% | 0.01 | −$365K | $2K | −$368K | Jun 15 |
| Q1 2026 · Jan 31 | $2.3M | −7.1% | 31.5% | −$95K | $33K | +285.0% | 0.00 | −$390K | $2K | −$393K | Mar 17 |
| Q4 2025 · Oct 31derived | $2.1M | −7.9% | 34.8% | −$133K | −$102 | −100.6% | 0.00 | $280K | $350 | $279K | Jan 29 |
| Q3 2025 · Jul 31 | $2M | −18.8% | 29.3% | −$314K | −$204K | — | -0.01 | $237K | $2K | $234K | Sep 14 |
| Q2 2025 · Apr 30 | $2.4M | +1.7% | 33.9% | −$98K | $95K | — | 0.00 | −$302K | $4K | −$306K | Jun 15 |
| Q1 2025 · Jan 31 | $2.5M | +3.8% | 31.1% | −$92K | $9K | — | 0.00 | −$429K | $0 | −$429K | Mar 17 |
| Q4 2024 · Oct 31derived | $2.3M | −35.2% | 31.1% | −$154K | $16K | — | -0.07 | $78K | $157K | −$79K | Jan 29 |
| Q3 2024 · Jul 31 | $2.4M | — | 26.3% | −$382K | −$309K | — | 0.01 | −$670K | $2K | −$672K | Sep 15 |
| Q2 2024 · Apr 30 | $2.4M | — | 26.0% | −$313K | −$214K | — | -0.01 | −$701K | $0 | −$701K | Jun 16 |
| Q1 2024 · Jan 31 | $2.4M | — | 22.5% | −$438K | −$271K | — | -0.01 | $726K | $820 | $725K | Mar 17 |
| Q4 2023 · Oct 31derived | $3.6M | — | 25.8% | −$52K | −$47K | — | — | $308K | −$2K | $310K | Jan 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Oct 31 | $9M | 32.3% | −$638K | −$100K | -1.1% | -0.00 | −$215K | $7K | −$222K | $31K | $1.7M |
| FY2024 · to Oct 31 | $9.5M | 26.5% | −$1.3M | −$778K | -8.2% | -0.03 | −$567K | $160K | −$726K | $11K | $1.7M |
| FY2023 · to Oct 31 | $17M | 29.8% | $1.1M | $1.3M | 7.7% | 0.06 | $1.9M | $7K | $1.9M | $34K | $1.7M |
| FY2022 · to Oct 31 | $19.4M | 25.2% | $1.2M | $1M | 5.2% | — | $592K | $19K | $573K | $82K | $3.4M |
| FY2021 · to Oct 31 | $20.1M | 26.6% | −$3.9M | −$2.1M | -10.4% | — | $805K | $11K | $794K | $26K | $1.7M |
| FY2020 · to Oct 31 | $21.6M | 30.9% | $2.2M | $2.1M | 9.5% | 0.09 | $1.5M | $56K | $1.5M | $2K | $1.7M |
Every number comes from Pharma-Bio Serv, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.